chevron_leftBack
As of 24 April 2025, Zealand Pharma A/S has a market cap of $4.37B USD, ranking #3137 globally and #22 in Denmark. It ranks #271 in the Healthcare sector, and #58 in the Biotechnology industry.
Key Stats
Market Cap
$4.37BUSD
28.7B DKK
Enterprise Value
$3.04BUSD
20.04B DKK
Revenue (TTM)
$9.56MUSD
62.69M DKK
EBITDA (TTM)
-$191.03MUSD
-1.26B DKK
Net Income (TTM)
-$164.45MUSD
-1.08B DKK
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Biotechnology
CEO
Adam Steensberg
open_in_new
Employees
335
Founded
1997
Website
zealandpharma.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| 0.3% | 0.4% | -29% | -47% | -52% | -35% |
Upcoming Earnings
Earnings Date
Thu, May 8
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
ZEAL
Zealand Pharma AS
ISIN: DK0060257814
Shares Out.:
Shares Outstanding:
70.678M1
Shares Float:
63.0M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
407.40 DKK | |
|
0NZU
Zealand Pharma AS
ISIN: DK0060257814
|
407.77 DKK | |
|
ZLDPF
Zealand Pharma AS
ISIN: DK0060257814
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
BA:
Barron's:
MS:
Morningstar:
|
63.00 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About Zealand Pharma A/S
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.
